TNF and rheumatoid arthritis: This provides a target for therapeutic intervention by blocking the action of TNFα; for example, with antibodies against TNFα such as infliximab, which is already being used in clinical practice to reduce peripheral inflammation in diseases such as rheumatoid arthritis or Crohn’s disease (36, 37).